Viral-mediated temporally controlled dopamine production in a rat model of Parkinson disease

Autor: Li, X.-G., Okada, T., Kodera, M., Nara, Y., Takino, N., Muramatsu, C., Ikeguchi, K., Urano, F., Ichinose, Hiroshi, Metzger, D., Chambon, P., Nakano, I., Ozawa, K., Muramatsu, S.-I.

Publikováno v: Molecular Therapy
Molecular Therapy, Cell Press, 2006, 13 (1), pp.160-6. ⟨10.1016/j.ymthe.2005.08.009⟩
Molecular Therapy, Nature Publishing Group, 2006, 13 (1), pp.160-6. ⟨10.1016/j.ymthe.2005.08.009⟩

International audience; Regulation of gene expression is necessary to avoid possible adverse effects of gene therapy due to excess synthesis of transgene products. To reduce transgene expression, we developed a viral vector-mediated somatic regulatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0093e6f4805eebf8fc2f4d9d106d6a3a

Behavioral Recovery in a Primate Model of Parkinson's Disease by Triple Transduction of Striatal Cells with Adeno-Associated Viral Vectors Expressing Dopamine-Synthesizing Enzymes

Autor: Muramatsu, S.-I., Kume, A., Matsumura, M., Nagatsu, I., Urano, F., Ichinose, Hiroshi, Nagatsu, T., Terao, K., Nakano, I., Ozawa, K., Fujimoto, K.-I., Ikeguchi, K., Shizuma, N., Kawasaki, K., Ono, F., Shen, Y., Wang, L., Mizukami, H.

Publikováno v: Human Gene Therapy. 13:345-354

One potential strategy for gene therapy of Parkinson's disease (PD) is the local production of dopamine (DA) in the striatum induced by restoring DA-synthesizing enzymes. In addition to tyrosine hydroxylase (TH) and aromatic-L-amino-acid decarboxylas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1da3163ea5c4b1abbc4d125a1811fe8
https://doi.org/10.1089/10430340252792486

Behavioral Recovery in 6-Hydroxydopamine-Lesioned Rats by Cotransduction of Striatum with Tyrosine Hydroxylase and Aromatic l-Amino Acid Decarboxylase Genes Using Two Separate Adeno-Associated Virus Vectors

Autor: Fan, D.-S., Ogawa, M., Fujimoto, K.-I., Ikeguchi, K., Ogasawara, Y., Urabe, M., Nishizawa, M., Nakano, I., Yoshida, M., Nagatsu, I., Ichinose, Hiroshi, Nagatsu, T., Kurtzman, G.J., Ozawa, K.

Publikováno v: Human Gene Therapy. 9:2527-2535

Parkinson's disease (PD) is characterized by the progressive loss of the dopaminergic neurons in the substantia nigra and a severe decrease in dopamine in the striatum. A promising approach to the gene therapy of PD is intrastriatal expression of enz

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::590b757fd7a4233a58cb8876d2ea0729
https://doi.org/10.1089/hum.1998.9.17-2527

Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease

Autor: Wang, L., Muramatsu, S., Lu, Y., Ikeguchi, K., Fujimoto, K., Okada, T., Mizukami, H., Hanazono, Y., Kume, A., Urano, F., Ichinose, Hiroshi, Nagatsu, T., Nakano, I., Ozawa, K.

Publikováno v: Gene therapy. 9(6)

Glial cell line-derived neurotrophic factor (GDNF) is a strong candidate agent in the neuroprotective treatment of Parkinson's disease (PD). We investigated whether adeno-associated viral (AAV) vector-mediated delivery of a GDNF gene in a delayed man

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::983103925174565e77e1457be6e9d244
https://pubmed.ncbi.nlm.nih.gov/11960314

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.